Back to top
more

Owens & Minor (OMI)

(Real Time Quote from BATS)

$16.00 USD

16.00
434,565

-0.13 (-0.81%)

Updated Aug 27, 2024 09:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to LabCorp (LH) Stock For Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.

Allscripts (MDRX) Unveils Newly Rebranded App Expo Site

by Zacks Equity Research

Allscripts' (MDRX) rebranded App Expo site to offer developers an opportunity to present their certified solutions online.

Here's Why You Should Retain Syneos Health (SYNH) For Now

by Zacks Equity Research

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe

by Zacks Equity Research

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing

by Zacks Equity Research

Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

by Zacks Equity Research

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch

by Zacks Equity Research

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.

Here's Why You Should Retain SmileDirectClub (SDC) For Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

by Zacks Equity Research

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

Medtronic (MDT) to Gain From New Reimbursement Program for CGM

by Zacks Equity Research

Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.

Bruker (BRKR) to Improve Spatial Biology With New Launch

by Zacks Equity Research

Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.

Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform

by Zacks Equity Research

The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.

Here's Why You Should Invest In Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Abbott (ABT) Gets FDA Approval for CardioMEMS HF System

by Zacks Equity Research

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

Here's Why You Should Hold on to STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.

Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union

by Zacks Equity Research

OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.

Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Should Value Investors Buy These Medical Stocks?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.